ABCG2 and hepatocellular carcinoma: Although BCRP/ABCG2 and MDR1 have been viewed as the two most important determinants for MDR in response to chemotherapy in HCC[28], [29], however, it remains unclear whether BCRP/ABCG2 expression is associated with HCC sensitivity to sorafenib.